MedTrace Logo

Long-term Safety of TPN171H Tablet in Erectile Dysfunction.

NCT06301854 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 472

Last updated 2025-07-25

No results posted yet for this study

Summary

This is a multicenter, open study to evaluate the long-term safety and efficacy of TPN171H in men with erectile dysfunction.

Conditions

Interventions

DRUG

TPN171H

10 mg/ time, as needed, it is recommended to take warm water within 0.5 to 4 hours before sexual activity.

Sponsors & Collaborators

  • Vigonvita Life Sciences

    lead INDUSTRY

Principal Investigators

  • Hui Jiang · Peking University First Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-04-12
Primary Completion
2025-06-05
Completion
2025-06-05

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06301854 on ClinicalTrials.gov